Inogen | INGN - Cash And Equivalent


Inogen reported $106.48M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Abbott USD 6.8B 1.72B Mar/2026
Accuray USD 41.29M 22.05M Dec/2025
AngioDynamics USD 41.64M 14.26M Sep/2025
Artivion USD 77.32M 21.55M Jun/2026
AtriCure USD 167.79M 21.62M Jun/2026
Baxter International USD 2.15B 133M Jun/2026
Becton, Dickinson and Co. USD 708M 105M Jun/2026
Boston Scientific USD 539M 914M Jun/2026
Cooper Companies USD 138.8M 13.9M Mar/2026
Dexcom USD 1.1B 13.2M Jun/2026
Edwards Lifesciences USD 2.9B 500M Jun/2026
Globus Medical USD 507.74M 53.2M Jun/2026
Inogen USD 106.48M 2.79M Sep/2025
Insulet USD 534.9M 54.5M Jun/2026
Medtronic USD 1.69B 258M Jun/2026
Orthofix International USD 103.81M 16.47M Jun/2026
Philips EUR 1.79B 803M Jun/2026
ResMed USD 1.47B 191.28M Jun/2026
Steris USD 482.3M 42.7M Jun/2026
Stryker USD 3.39B 513M Jun/2026
Tandem Diabetes Care USD 62.82M 116.51M Jun/2026
Teleflex USD 300.16M 9.25M Jun/2026
X T L Biopharmaceuticals USD 76K 295K Dec/2025
Zimmer Biomet Holdings USD 410M 14.2M Jun/2026